Iranian Stem Cell Council Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2015
NCT04078308
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Iranian Stem Cell Council

Active Ingredients

Drugs in Phase 2 Trials (1)

bone marrow derived mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1